Thursday July 28, 2022
Chair’s Investor Update
Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces an Investor Update from its Chair, Nick […]
Thursday July 28, 2022
Chair’s Investor Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Chair’s Investor Update Brighton, United Kingdom – 28 July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused […]
Tuesday July 26, 2022
Publication of new data on NTCD-M3
Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces publication of new data on NTCD-M3, its […]
Tuesday July 26, 2022
Publication of new data on NTCD-M3
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections Brighton, United Kingdom – 26 July 2022 […]
Tuesday July 19, 2022
Positive update from US FDA on XF-73 Phase 3
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans FDA clarifies Phase 3 and US registration pathway […]
Tuesday July 12, 2022